Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · IEX Real-Time Price · USD

3.830

+0.130 (3.51%)

At close: Apr 26, 2024, 4:00 PM

3.910

+0.080 (2.09%)

After-hours: Apr 26, 2024, 4:11 PM EDT

Relmada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Selling, General & Admin	48.89	47.93	35.08	24.87	7.25	3.97	5.93	10.01	9.23
Research & Development	54.81	113.32	90.62	35.97	7.86	2.94	1.29	6.21	7.87
Operating Expenses	103.7	161.25	125.7	60.84	15.11	6.92	7.22	16.22	17.1
Operating Income	-103.7	-161.25	-125.7	-60.84	-15.11	-6.92	-7.22	-16.22	-17.1
Interest Expense / Income	0	0	0	0	0.1	1.34	0	0	0
Other Expense / Income	-4.91	-4.21	0.05	-1.38	-0.21	0.71	-0.93	-13.24	3.7
Pretax Income	-98.79	-157.04	-125.75	-59.46	-15.01	-8.96	-6.29	-2.97	-20.8
Net Income	-98.79	-157.04	-125.75	-59.46	-15.01	-8.96	-6.29	-2.97	-20.8
Shares Outstanding (Basic)	30	30	18	16	9	3	3	3	2
Shares Outstanding (Diluted)	30	30	18	16	9	3	3	3	2
Shares Change	1.59%	68.80%	12.56%	68.75%	194.65%	3.90%	4.10%	16.68%	-
EPS (Basic)	-3.28	-5.30	-7.16	-3.81	-1.62	-2.86	-2.08	-1.04	-8.36
EPS (Diluted)	-3.28	-5.30	-7.16	-3.81	-1.62	-2.86	-2.08	-1.04	-8.36
Free Cash Flow	-51.66	-103.8	-91.87	-27.81	-12.09	-6.01	-6.52	-13.71	-16.25
Free Cash Flow Per Share	-1.72	-3.50	-5.23	-1.78	-1.31	-1.92	-2.16	-4.73	-6.54
EBITDA	-98.79	-157.04	-125.75	-59.45	-14.9	-7.62	-6.2	-2.92	-20.79
Depreciation & Amortization	0	0	0	0	0	0	0.09	0.05	0.01
EBIT	-98.79	-157.04	-125.75	-59.46	-14.9	-7.62	-6.29	-2.97	-20.8

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).